Business
Convertible Loan Notes & Total Voting Rights
Convertible Loan Notes & Total Voting Rights.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0061E\n Scancell Holdings Plc\n 02 November 2020\n \n \n \n 2 November 2020\n \n Scancell Holdings plc\n (\"Scancell\" or the \"Company\")\n \n Conversion of Convertible Loan Notes\n \n and Total Voting Rights\n \n Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that funds managed by Redmile Group, LLC (\"Redmile Funds\"), a holder of unsecured convertible loan notes issued by the Company in August 2020 (the \"CLNs\"), has today converted approximately £3.25 million in principal amount of CLNs into new ordinary shares of £0.001 each in the capital of the Company (\"Ordinary Shares\").\n \n In accordance with the terms of the CLN instrument, 53,326,124 new Ordinary Shares (the \"New Shares\") have been issued to Redmile Funds on conversion of its CLNs. Following the issue of the New Shares, Redmile Funds' shareholding is 237,306,384, which is approximately 29.97 per cent. of the enlarged share capital. The remaining principal amount of Redmile Funds' CLNs is approximately £1.75 million. \n \n The New Shares rank pari passu with the existing issued Ordinary Shares. Following the issue of the New Shares, the Company's enlarged share capital comprises 791,917,828 Ordinary Shares with voting rights. This figure may therefore be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the issued share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The New Shares have been admitted to trading on AIM pursuant to the block admission of the CLNs which became effective on 12 August 2020.\n \n \n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Scancell Holdings plc\n \n \n +44 (0) 20 3727 1000\n \n \n \n \n Dr John Chiplin, Executive Chairman\n \n \n \n \n \n \n \n Dr Cliff Holloway, CEO\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Panmure Gordon (UK) Limited\n \n \n +44 (0) 20 7886 2500\n \n \n \n \n Freddy Crossley/Emma Earl (Corporate Finance)\n \n \n \n \n \n \n \n...